CVE-2026-21970 represents a medium-severity vulnerability in the Oracle Life Sciences Central Designer product, specifically within Oracle Health Sciences Applications. The affected version is 7.0.1.0. This vulnerability allows a low-privileged attacker with network access via HTTP to compromise the Oracle Life Sciences Central Designer system. Successful exploitation can lead to unauthorized access to critical data or complete access to all data accessible within the system.
The CVSS 3.1 Base Score for this vulnerability is 6.5, indicating a significant risk due to potential confidentiality impacts. Organizations with this software should be aware of the implications of this vulnerability and take immediate action. Given the potential for sensitive information exposure, the urgency for defenders is high.
As of now, there is no known public exploit for this vulnerability, and it has not been included in the Known Exploited Vulnerabilities (KEV) catalog. However, the ease of exploitation combined with the potential consequences of a successful attack emphasizes the need for prompt remediation.
Organizations should prioritize patching immediately to mitigate the risks associated with this vulnerability.
Vulnerability Details
CVE-2026-21970 is characterized by the following attributes:
Official CVE Description: Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). The supported version that is affected is 7.0.1.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized access to critical data or complete access to all Oracle Life Sciences Central Designer accessible data.
CVSS Score: 6.5 (Medium Severity) - This score reflects the potential impact on confidentiality. The attack vector is NETWORK, with low complexity and low privileges required. No user interaction is necessary for exploitation.
Affected Product: Oracle Life Sciences Central Designer, affected version 7.0.1.0.
Publication Date: January 20, 2026.
Technical Analysis
The root cause of CVE-2026-21970 stems from inadequate access controls within the Oracle Life Sciences Central Designer. Attackers may leverage this vulnerability due to its low complexity and low privileges required for exploitation. The attack vector is network-based, allowing a low-privileged attacker to initiate an attack without user interaction.
The impact on confidentiality is high, as successful exploitation can compromise sensitive data stored within the application. However, integrity and availability impacts are not applicable in this case.
Risk & Impact Analysis
Risk to organizations includes unauthorized access to critical data, which could lead to data breaches and loss of sensitive information. Given the nature of the application, the potential blast radius is significant, affecting any organization utilizing the Oracle Life Sciences Central Designer. Organizations should address this vulnerability in their priority patch cycle to prevent exploitation.
The medium severity rating implies that while immediate exploitation may not be prevalent, the vulnerability poses a distinct risk that should not be overlooked. Organizations are urged to implement remediation measures promptly.
Exploitation Status
Signal | Status |
|---|---|
Known Exploit | No |
Public PoC | No |
Actively Exploited | No |
Ransomware Use | No |
Affected Versions
The affected version of Oracle Life Sciences Central Designer is 7.0.1.0. All versions prior to vendor patch are considered vulnerable.
Mitigation & Remediation
Organizations should apply the latest patches provided by Oracle to remediate this vulnerability. For detailed patch information, refer to the Oracle Critical Patch Update Advisory. If immediate patching is not possible, organizations should consider implementing strong network controls to limit access to the affected system.
Penetration testing can also help identify vulnerabilities in the system proactively.
Detection Guidance
Monitor logs for any unauthorized access attempts to the Oracle Life Sciences Central Designer. Look for unusual patterns in user access that may indicate exploitation attempts. Additionally, network traffic should be analyzed for any suspicious requests to the vulnerable application.
AppSecure Threat Intelligence Insight
The long-term significance of CVE-2026-21970 lies in its demonstration of the ongoing need for robust security practices in application development. It highlights the importance of regular updates and monitoring of software components to prevent potential vulnerabilities from being exploited.
Security teams should take note of this incident as a pattern of vulnerabilities that can arise from inadequate access controls. Proactive measures, including regular security assessments and vulnerability management programs, are essential to safeguarding sensitive data in the long run.
Organizations must recognize that even medium-severity vulnerabilities can have a profound impact and should prioritize their remediation efforts accordingly.
Security testing is a vital component to ensure that such vulnerabilities are identified and addressed before they can be exploited.
API security testing should also be considered as part of an organization's overall security strategy.
Disclaimer: This content was generated using AI. While we strive for accuracy, please verify critical information with official sources.
.webp)